Manhattan Medical Research | New York, NY

Research site

(Unclaimed)

Location

215 Lexington Avenue, 21st Floor, New York, New York, United States of America

Site insights

Top conditions

Top treatments

Elagolix

UGN-102

LY3298176

Metformin

Estradiol

LY900014

Tirzepatide

IX-01

Norethindrone Acetate

Tradipitant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 42 total trials

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

This study is being conducted to evaluate the safety and determine the recommended Phase 2 dose (RP2D) of UGN-301 (zalifrelimab) administered intrave...

Enrolling

Carcinoma in Situ of Bladder

Non-muscle Invasive Bladder Cancer

Drug: UGN-301

Drug: Gemcitabine

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (ENVISION)

This Phase 3, multinational, single-arm study was designed to evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patient...

Active, not recruiting

Bladder Cancer

Urothelial Carcinoma

Drug: UGN-102

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

This is a Phase Ib/IIb, randomized, two-cohort, open-label, multicenter study of intravesical N-803 plus BCG versus BCG alone, in BCG naïve patients...

Enrolling

Non-muscle Invasive Bladder Cancer

Biological: BCG( 50mg/Instillation)

Biological: BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). )

A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years

The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placeb...

Enrolling

Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention

Biological: ExPEC9V

Other: Placebo

Butterfly Pivotal Study

A prospective, multicenter, blind randomized (2:1) controlled study comparing the International Prostate Symptom Score (IPSS) of the Active arm to th...

Enrolling

BPH (Benign Prostatic Hyperplasia)

Lower Urinary Tract Symptoms (LUTS)

Device: Butterfly Prostatic Retraction Device

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

This is a Phase II/III, open-label, single-arm, multicenter study of intravesical BCG plus N-803 or N-803 only in patients with BCG unresponsive high...

Active, not recruiting

Bladder Cancer

Drug: N-803 and BCG

Drug: N-803